Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)

Conditions:   Neoplasms;   Non-small Cell Lung Carcinoma;   Head and Neck Neoplasms;   Urinary Bladder Neoplasms;   Stomach Neoplasms
Interventions:   Biological: MK-7684;   Biological: pembrolizumab
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2017

http://ift.tt/2qd4QMV